T1	Participants 221 304	Thirteen GH-deficient adults (4 females, 9 males; mean (SEM) age 26.4 (1.7) years),
T2	Participants 734 748	placebo period
T3	Participants 982 997	normal subjects
T4	Participants 1210 1225	normal subjects
T5	Participants 1436 1451	normal subjects
T6	Participants 1758 1767	patients.
